

This communication should be viewed by:

Primary Care Providers Behavioral Health Providers Clinical Staff

COVID-19 Vaccination Coverage Update

To keep our valued care delivery partners up to date, MVP Health Care® (MVP) is sharing that on September 11, 2023 the Food and Drug Administration (FDA) approved the updated vaccines by Pfizer-BioNTech and Moderna. Additionally, the FDA approved Novavax on October 3, 2023.

MVP covers approved COVID-19 vaccines at no cost-share to Members in all plans when administered by Participating Providers.

*MVP will reimburse Providers for the COVID-19 vaccines as well as the administration when the guidance below is followed:

Pfizer Vaccine			
Code	Description	Age Range	Administration Code
91318	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent	6 months through 4 years	90480
91319	reconstituted, tris-sucrose formulation, for intramuscular use. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, preservative free 10mcg/0.2 mL dosage, tris-sucrose formulation, for intramuscular use.	5 years through 11 years	90480
91320	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, preservative free 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use.	12 years and older	90480
	Moderna Vaccine		
91321	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, preservative free, 25 mcg/0.25 mL dosage for intramuscular use.	6 months through 11 years	90480
91322	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, preservative free, 50 mcg/0.5 mL dosage for intramuscular use.	12 years and older	90480
	Novavax COVID-19 Vaco	cine	
91304	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, 5mcg/0.5 mL dosage, for intramuscular use.	12 years and older	90480

^{*} All previous COVID-19 vaccination codes have been terminated and will no longer be valid as of November 1, 2023

It's Time to Recertify Your Patients!*

The Families First Coronavirus Response Act has expired. To learn how MVP can help your patients continue their coverage, visit **mvphealthcare.com/recertification.**

*Applies to Members enrolled in Medicaid, Child Health Plus (CHP), Health and Recovery Plan (HARP), and the Essential Plan (EP).

